A New Gene-Based Pattern That May Predict Survival and Immune Response in Bone Cancer Patients

Osteosarcoma (OS) constitutes a malignant neoplasm originating from mesenchymal cells, giving rise to malignant spindle stromal cells that mimic bone tissue [1]. These tumor cells exhibit distinctive characteristics, capable of generating immature osteoid cells. Early clinical manifestations of OS commonly include pain and the presence of a localized mass, contributing to the heightened challenge of accurately diagnosing or recognizing OS during its initial phases. Positioned as the predominant primary bone tumor among adolescents, OS ranks as the third most prevalent cancer, following lymphoma and brain cancer [2]. Incidence primarily affects children and adolescents, yet noteworthy occurrences also arise in individuals above 60 years of age. The global incidence of OS stands at approximately 1–3 cases per million individuals annually [3]. Notably aggressive local invasion and early metastasis serve as primary hallmarks of OS malignancy. The lung represents the most frequent site of metastasis, with a majority of OS patients developing lung metastases within 1 year postdiagnosis, subsequently leading to a dismal prognosis [1]. The prevailing standard of clinical intervention for OS involves extensive surgical resection, coupled with neoadjuvant and adjuvant chemotherapy [4]. Presently, adjuvant chemotherapy post-tumor resection exhibits efficacy in managing OS patients. Despite advancements, this therapeutic approach enhances the 10-year survival rate to roughly 50%; however, patients with metastatic OS continue to endure low survival rates [2]. Substantial progress in elevating survival rates for OS patients remains elusive. Hence, further comprehensive investigations into OS are imperative to enhance therapeutic effectiveness and overall survival rates.

Cells undergo growth and differentiation under physiological conditions, whereas apoptosis is triggered in response to aberrant circumstances. The spatial positioning of cells within tissues necessitates specific mediators, such as the extracellular matrix (ECM), and precise interactions with neighboring cells [5]. The equilibrium of normal tissue relies on the essential processes of cell proliferation and apoptosis. Notably, in the absence of ECM, typically adherent cells undergo a distinct form of apoptotic demise known as anoikis [6]. Integrin, despite lacking a kinase domain, serves as a pivotal factor in mediating ECM adhesion. It interfaces with other molecules to transmit signaling cues, thereby regulating fundamental cellular functions encompassing proliferation, survival, and migration [6]. Anoikis, as a specialized form of apoptotic cell death, is triggered by the disruption of cell/ECM interactions, presenting unique signals that instigate cell demise distinct from other proapoptotic stimuli. This process unfolds in response to extensive loss of cell adhesion, deploying diverse signaling and apoptotic pathways, but is not a singular inducer of cell death [5]. Specifically, anoikis occurs due to inadequate or inappropriate cell–matrix interactions, contributing significantly not only to tissue equilibrium and development but also to carcinogenic processes [7]. It represents a programed cell death mechanism that materializes when cells are separated from the appropriate ECM, thereby impeding integrin connections and preventing cellular dysplasia or attachment to unsuitable substrates [8]. Anoikis assumes a pivotal role in maintaining tissue homeostasis and development by forestalling isolated epithelial cells from establishing colonies elsewhere. Moreover, its dysregulation in certain diseases underscores its involvement in the physiological processes governing tissue equilibrium and development [8].

Anoikis functions as a barrier to cellular metastasis, a phenomenon precipitated by the detachment of cells from the ECM or neighboring cellular entities. Tumor cells harboring malignant propensities have evolved intricate antioxidant mechanisms to endure detachment from their original site and traverse through the lymphatic and circulatory systems. Anomalies within the caspase-activated death receptor pathway, such as the overexpression of FLIP, can engender cellular resistance to anoikis [9]. Consequently, cells resilient to anoikis can circumvent signals triggering death due to detachment, thereby prolonging their survival during migration to secondary sites. Consequently, the resistance to anoikis has been recognized as a pivotal step in the genesis of tumors [10], fostering prolonged survival of detached cells and contributing significantly to cellular immigration and regeneration. Anomalous regulation of anoikis has been designated as a hallmark of malignant transformation, leading to the development of resistance to anoikis and consequent pathogenesis [11]. This underscores a close association between anomalous regulation of anoikis, early metastasis, and overall survival, suggesting anoikis as a pivotal barrier to cellular metastasis. Empirical evidence indicates the contributory role of Src activity in conferring tolerance to anoikis in human SAOS-2 cells. Overexpression of Src has been identified in anoikis-resistant SAOS cells, and the pharmacological inhibition of its activity has demonstrated the restoration of sensitivity to anoikis [11]. The collaborative action of the RanBP9/TSSC3 complex has been revealed to suppress anoikis resistance and metastasis in OS by impeding Src-mediated Akt signaling [12]. Notably, human OS cells exhibiting resistance to anoikis exhibit pronounced angiogenesis by activating the MAPK pathway mediated by Src kinase [13]. Furthermore, anoikis resistance mediated by FASN has been found to promote the growth and metastasis of OS [14]. Metastasis, a multifaceted biological process inherent in most solid tumors, stands as the primary cause of cancer-associated mortality. Consequently, therapeutic interventions aimed at impeding metastasis may serve as compensatory strategies in the battle against cancer.

The utilization of risk prognostic models holds considerable promise in the accurate anticipation of tumor prognosis. These novel models are increasingly employed to forecast the prognostic outcomes among patients affected by diverse tumor types. Specifically, within pediatric populations, a hypoxia gene-based signature has exhibited the capability to predict survival rates while exerting influence on the tumor's immune microenvironment [15]. Moreover, the development of an autophagy-related clinical prognosis model has been instrumental in forecasting overall survival in OS cases [16]. Notably, in the context of OS, a recent approach involving a novel pyroptosis-related signature has proven effective in prognostication and the identification of immune microenvironment characteristics [17]. Another recent investigation has successfully developed a cuproptosis-related long non-coding RNA (lncRNA) risk prognostic model tailored to guide prognosis and assess the immune microenvironment among OS patients [18]. Presently, our study contributes by constructing a pioneering risk prognostic model based on anoikis-related genes (ARGs) to delineate the survival prospects and immune microenvironmental in OS patients. This newly devised prognostic model exhibits efficacy in predicting survival outcomes for individuals with OS.

In preceding investigations, several prognostic models were developed via bioinformatics analyses to investigate genes or lncRNAs associated with OS prognosis. The bioinformatics exploration of OS predominantly centers on the anticipation of OS-related genes. Distinguishing itself from prior research endeavors, this study innovatively incorporates the anoikis phenotype. The genes identified through the establishment of the prognostic model in this investigation exclusively consist of ARGs, which may actively participate in the progression of OS through the phenomenon of anoikis. Within the context of this study, an innovative prognostic model was formulated to systematically examine the prognostic outcomes of patients with OS, with a specific emphasis on the phenomenon of anoikis. The findings of this research contribute to the body of knowledge pertaining to OS prognosis. Furthermore, a more in-depth examination of the ARGs encompassed within the model holds the potential to significantly enhance clinical decision-making for patients afflicted with OS.

In this investigation, a training cohort was established utilizing the TCGA database, complemented by a validation cohort sourced from the GEO database. Through a comprehensive analysis of both repositories, a pioneering prognostic model predicated on ARGs was formulated. This model demonstrated notable efficacy in forecasting the survival prospects of patients diagnosed with OS, while concurrently offering insights into modulating the immune microenvironment among OS patients. Notably, the developed prognostic model exhibited the capability to forecast metastatic occurrences in OS patients. The construction of the model relied on the integration of 11 ARGs, among which CBS, MYC, MMP3, CD36, SCD, COL13A1, and HSP90B1 were classified as high-risk ARGs, whereas VASH1, TNFRSF1A, PIP5K1C, and CTNNBIP1 were categorized as low-risk ARGs. Patients grouped within the high-risk category demonstrated diminished immune scores encompassing immune cell populations and immune functionality compared to their low-risk counterparts. Specifically, a significant downregulation of CD8+ T cells, neutrophils, and TIL was observed within the high-risk cohort, along with a decrease in checkpoint molecules and T cell coinhibition markers. Furthermore, the authors identified 19 genes linked to immune checkpoints, such as CD200R1, HAVCR2, and LAIR1, which exhibited decreased expression levels in high-risk OS patients. Additionally, a nomogram model was developed by the authors, proving effective in prognosticating the outcomes for OS patients. Lastly, leveraging the risk prognostic model, the authors identified eight pharmaceutical agents displaying sensitivity. Bortezomib, Midostaurin, CHIR.99021, and JNK.Inhibitor.VIII were found to be more effective in low-risk OS patients, whereas Lenalidomide, Sunitinib, GDC0941, and GW.441756 exhibited greater sensitivity in high-risk OS patients. RT-qPCR was employed to authenticate 11 ARGs within the risk prognosis model. The findings elucidated that CBS, MYC, MMP3, and PIP5K1C exhibited diminished expression levels in OS, while CD36, SCD, COL13A1, HSP90B1, VASH1, and CTNNBIP1 manifested heightened expression levels in the context of OS.

The protein product derived from the CBS gene functions as a homotetramer, facilitating the enzymatic conversion of homocysteine to cystathionine—a pivotal initial step in the transsulfuration pathway. Allosteric activation of the encoded protein is achieved through adenosyl-methionine, with pyridoxal phosphate serving as a requisite cofactor. Genetic aberrations within this gene have been implicated in the manifestation of cystathionine beta-synthase deficiency (CBSD), a pathological condition associated with homocystinuria. The CBS1 domains, also referred to as CBS motifs, exert regulatory control over the functionality of numerous proteins across a spectrum of organisms, spanning from bacteria to humans. Notably, the CBS domain serves not only as a discerning energy sensor, modulating cellular activities in response to fluctuations in environmental cues but also as a regulator of intracellular chloride pathways, nitrate transit, and pyrophosphatase behavior [24]. CBS has also shown promise in predicting OS prognosis. Investigations suggest a downregulation of CBS in OS [25]. Moreover, recognized as both ferroptosis-related and immunogenic cell death-related genes, CBS not only forecasts OS patient survival but also significantly influences tumor chemoresistance [26–28]. This current study posits CBS as an ARG for appraising the prognosis of OS patients, further substantiating its prognostic relevance within this context. The MYC gene represents a proto-oncogene, characterized by its encoding of a nuclear phosphoprotein pivotal to the regulation of cell cycle progression, apoptosis, and cellular transformation. The resultant protein establishes a heterodimeric association with the cognate transcription factor MAX. Notably, amplification of this gene is frequently observed in various human malignancies. Diverse cellular processes such as cell development, cell cycle modulation, differentiation, apoptosis, angiogenesis, metabolism, DNA repair, protein translation, immune response, and stem cell formation are intrinsically influenced by MYC, primarily operating as a transcriptional regulatory factor [29]. Targeting MYC presents a promising avenue in cancer therapeutics owing to its ubiquitous dysregulation as a driver gene in human cancers [29]. Pertinently, studies elucidate that MYC inhibition reshapes the tumor immune microenvironment in OS by recruiting T lymphocytes and engaging the CD40/CD40L system [30]. Additionally, the interplay between miR-193b and MYC has been associated with decelerating the progression and metastasis of OS [31]. Noteworthy potential biomarkers for forecasting the trajectory and prognosis of OS, thereby improving clinical therapeutic strategies, encompass the evaluation of c-MYC protein expression and the apoptosis index [32]. This reinforces the close linkage of MYC with OS and underscores its predictive value, further corroborating the findings of this study. The members of the MMP family play integral roles in the degradation of the ECM during various physiological phenomena, including embryonic development, reproductive processes, and tissue remodeling. Additionally, these enzymes are implicated in pathological conditions such as arthritis and metastasis. The majority of MMPs are initially secreted as inactive proproteins, a state from which they undergo activation through cleavage by extracellular proteinases. Extracellular vesicles play a pivotal role in facilitating the molecular transfer of MMP3, thereby augmenting tumor proliferation and onset. This underscores MMP3 as a multifaceted determinant crucial for tumor progression [33]. Combining MMP3 therapy with oncolytic virus therapy presents a promising avenue in cancer therapeutics [34]. Studies underscore miR-134′s capacity to target MMP1 and MMP3, effectively impeding OS cell invasion and metastasis both in vitro and in vivo [35]. Additionally, compounds like the curcumin analog DK1 can suppress prometastatic genes and proteins including MMP3, thereby reducing the metastatic and angiogenic potential of OS cell lines [36]. Notably, MMP3 has been implicated in stimulating tumor cell metastasis in OS [36]. This study identifies MMP3 as a high-risk actionable predictive gene in OS, indicating its role as an independent prognostic factor in our risk prognostic model. These findings align coherently with earlier investigations, affirming the consistency of the results presented herein.

The protein encoded by CD36 constitutes the fourth principal glycoprotein situated on the surface of platelets, functioning as a receptor for thrombospondin in both platelets and diverse cellular lineages. Given the ubiquitous presence of thrombospondins, proteins with broad distribution participating in numerous adhesive processes, it is plausible that this particular protein assumes pivotal roles as a cell adhesion molecule. The transmembrane glycoprotein CD36 serves as a crucial regulator influencing various cellular processes such as apoptosis, immune detection, inflammation, and lipid uptake. Its involvement in reprograming lipid metabolism and modulating tumor-associated immune cells has been associated with cancer growth and the establishment of tumor immune tolerance [37]. The potential targeting of CD36 in cancer therapy has been proposed due to these multifaceted roles. Studies have indicated a correlation between CD36 and OS progression. Specifically, downregulation of the thrombospondin receptor CD36 by ribozymes has been observed to decelerate the development of the human OS cell line [38]. However, uncertainties persist regarding the specific contribution of CD36 to OS evolution. Our research indicates that CD36, identified as a high-risk prognostic gene, not only serves as a predictor of OS survival but also exerts influence over the immune microenvironment within OS. SCD gene encodes an enzymatic entity intricately implicated in the intricate processes of fatty acid biosynthesis, with a principal focus on the synthesis of oleic acid. The encoded protein is a constituent of the fatty acid desaturase family and assumes the characteristic feature of an integral membrane protein, spatially localized within the endoplasmic reticulum. Notably, the enzymatic production of monounsaturated fatty acids by SCD has been linked to critical cellular processes encompassing cell development, survival, differentiation, metabolic regulation, and signaling. In the context of cancer, SCD contributes to metabolic reprograming along canonical Wnt signaling pathways and activation of YAP, thereby promoting stemness and tumorigenesis [39]. Consequently, the role of SCD as a potential therapeutic target in cancer treatment has gained attention due to its pivotal involvement in tumor lipid metabolism and membrane architecture [40]. Furthermore, upregulation of SCD-1 has been identified as exerting a self-protective impact in MG63 OS cells following high shear force injury [41]. Our analysis underscores the prognostic value of CD36 and SCD in predicting OS patient survival, opening new avenues for research into enhancing OS prognosis. The COL13A1 gene encodes an alpha chain of nonfibrillar collagens, the precise functional attributes of which remain enigmatic. Nevertheless, its discernible expression within cells responsible for the synthesis of connective tissue, albeit at minimal levels, intimates a conceivable overarching involvement in the regulation of connective tissues. Earlier research has identified COL13A1 as a prognostic gene in OS, influencing patient survival through immune-related multiomics studies [42]. COL13A1 emerges as a predictive marker for OS patient outcomes, impacting pyroptosis prognoses and DNA methylation control [43, 44]. This study reaffirms the prognostic significance of COL13A1 as an ARGs for OS, shedding light on its pivotal role in predicting OS patient outcomes. HSP90B1 pertains to a constituent within the adenosine triphosphate (ATP)-metabolizing molecular chaperone family, exhibiting pivotal functions in the stabilization and folding of diverse proteins. The specified protein is predominantly situated in melanosomes and the endoplasmic reticulum. Notably, the expression of this protein is implicated in various pathogenic conditions, including the initiation of tumorigenesis. HSP90B1, known as gp96, functions as a chaperone for TLRs and is expressed in T-cells, primarily localizing to the endoplasmic reticulum [45]. Despite its previous association with OS survival [46], the precise mechanistic connection between HSP90B1 and OS survival remains ambiguous. This study delineates HSP90B1 as a high-risk gene associated with OS development, with increased expression correlating with an unfavorable prognosis for OS patients. The insights from this investigation significantly advance our understanding of OS survival dynamics, emphasizing the critical role of HSP90B1 therein.

The VASH1 protein demonstrates the capacity for actin-binding activity and metallocarboxypeptidase activity. It plays a pivotal role in the negative regulation of angiogenesis, suppression of blood vessel endothelial cell migration, and mediation of proteolytic processes. Activated vascular endothelial cells demonstrate a heightened preference for expressing VASH1, an emerging endogenous modulator of angiogenesis. Numerous malignancies, such as upper urinary tract urothelial carcinoma, ovarian carcinoma, squamous cell carcinoma of the esophagus, renal cell carcinoma, and breast carcinoma, exhibit significant VASH1 expression based on several studies [47]. Nonetheless, scant investigations have explored VASH1's correlation with OS, with limited reports indicating its role in obstructing adriamycin resistance in OS cells through activation of the protein kinase B signaling pathway [48]. This study unravels the prognostic influence of VASH1, categorized as a low-risk ARG, on the survival of OS patients. As such, this work heralds a novel avenue for delving into the prognosis and clinical management of OS. The TNFRSF1A gene serves as the encoding locus for a constituent of the tumor necrosis factor (TNF) receptor superfamily. The ensuing receptor experiences proteolytic cleavage, thereby releasing its soluble variant capable of interacting with unbound TNF-α, thereby mitigating inflammatory responses. This interaction assumes significance in cellular processes such as survival, apoptosis, and inflammation, as elucidated in prior investigations [49]. Earlier research has underscored the prognostic relevance of the pyroptosis-related gene TNFRSF1A concerning OS patients' survival [43]. This investigation showcases TNFRSF1A's potential as an ARG for predicting the prognosis of OS patients, emphasizing its utility in forecasting their survival. CTNNBIP1 is the gene responsible for encoding a protein that interacts with β-catenin, thereby operating as a negative regulator within the intricate Wnt signaling pathway. The precise classification of its role as either a tumor suppressor or an oncogene in various cancer types is currently a matter of considerable debate in the scientific community [50]. Studies have highlighted CTNNBIP1's influence on OS patient survival by functioning as both a ferroptosis- and pyroptosis-related gene [51, 52]. This study identifies CTNNBIP1 as a low-risk gene when analyzing OS patient survival as an ARG, opening avenues for expanded research in this domain. PIP5K1C encodes a type I phosphatidylinositol 4-phosphate 5-kinase, a pivotal enzyme instrumental in the phosphorylation of phosphatidylinositol 4-phosphate, thereby generating phosphatidylinositol 4,5-bisphosphate. This enzymatic entity is prominently localized at synapses and has been discerned to actively participate in cellular processes such as endocytosis and cell migration. Notably, mutations occurring at this specific genomic locus have been causally linked to the manifestation of lethal congenital contractural syndrome. The association between PIP5K1C and OS lacks conclusive evidence. To the best of my knowledge, this study marks the initial identification of PIP5K1C's impact on the immunological microenvironment and prognosis of OS patients. This newfound discovery advocates for a fresh inquiry aimed at enhancing the clinical effectiveness and prognostication of OS.

The depletion of T cells constitutes a pivotal element in OS pathophysiology [53]. Research findings indicate that individuals with heightened OS risk factors exhibit diminished overall counts of CD8+ T cells. Furthermore, investigations revealed the involvement of C3 TXNIP+ and C5 IFIT1+ macrophages in the regulation of regulatory T cells and their participation in the exhaustion of CD8+ T cells. This underscores the potential of immunotherapeutic interventions capable of targeting both CD8+ T cells and macrophages [53]. A comprehensive study on the hypoxic-related prognosis model of OS demonstrated the downregulation of five distinct immune cell types—DCs, macrophages, neutrophils, pDCs, and TIL—as well as three distinct immunological functions—CCR, APC coinhibition, and checkpoint signaling—in the high-risk group [54]. Moreover, the ARGs risk prognosis model developed in this research indicated reduced expression of neutrophils, TIL, and checkpoint genes in the high-risk group of OS patients. Contrasting metastatic OS with nonmetastatic OS, the latter exhibited higher quantities of CD56 bright natural killer cells, immature B cells, M1 macrophages, and neutrophils, while the former demonstrated lower levels of M2 macrophages [55]. The study identified tumor metastasis as an independent prognostic factor in the ARGs-based risk prognosis model and noted reduced neutrophil expression in the high-risk group and patients with metastatic OS. TIL have been implicated in the progression of various malignancies. Moreover, TIL therapy, having shown success in treating multiple malignancies such as melanoma, may emerge as a potentially effective approach for adult OS treatment [56]. The expression of T cell coinhibition-related genes is notably diminished in the high-risk group, a characteristic evident in the zinc finger protein gene-based prognostic marker for OS, further supported by a cuproptosis-related lncRNAs-based OS risk prognostic model [18, 57].

In our analysis focusing on the prognostic factors in OS, our ARGs risk prognosis model revealed significantly diminished expression of three immune checkpoint-related genes: CD200R1, HAVCR2, and LAIR1 in the high-risk group. Existing literature suggests that HAVCR2 serves as an immunological marker for OS and holds potential significance in determining patient prognosis [51]. Furthermore, elevated expression of HAVCR2, an immune checkpoint, is associated with better OS prognosis [58]. Utilizing pyroptosis-related lncRNAs, a risk-predictive model for OS underscored the underexpression of LAIR1 within high-risk populations [59]. Notably, in OS cells, overexpression of LAIR1 led to decreased expression of glucose transporter-1 and hindered the production of components linked to epithelial-mesenchymal transition [60]. Conversely, there remains an absence of reported correlation between CD200R1 and OS. Our study unveiled decreased expression of the immune checkpoint-related gene CD200R1 in the high-risk group identified through the ARGs-based OS risk prognosis model. This novel discovery introduces a promising avenue for further investigations into OS survival research, potentially contributing to advancements in OS immunotherapy strategies. Moreover, it is imperative to direct attention toward immunoactivation or inhibition markers such as CTLA4 and LAG3. Immunotherapy has emerged as a promising therapeutic strategy for the treatment of human malignancies. The evasion of immune surveillance is widely acknowledged as a significant contributor to malignant progression. Notably, suppressor receptors, particularly CTLA4 and PD1, play a pivotal role in mediating antitumor immune effects [61]. Evidence reveals an augmented expression of CTLA4 and an increased proportion of monocytes in patients diagnosed with OS [62]. The polymorphism of the CTLA4 gene may exhibit an association with the risk of OS in the Chinese Han population, thereby serving as a molecular marker for assessing the OS risk [63]. In patients with OS, particularly those with metastatic or pathological fractures, there is a noteworthy upregulation of PD1 expression in T cells [64]. The concurrent blockade of CTLA4 and PD1 emerges as an attractive immunotherapeutic approach for patients grappling with drug-resistant or metastatic OS [61]. Additionally, a compelling finding suggests that the triple blockade of CTLA4, PDL1, and TIM3 represents an effective strategy for inhibiting the progression and migration of tumor cells in OS [65].

The in vitro invasive capacity of OS cells is notably attenuated by bortezomib, an established anticancer medication categorized as a selective and reversible inhibitor of the ubiquitin-dependent proteasome system. This compound induces cancer cell cycle arrest and apoptosis [66]. Concurrent administration of kinase inhibitors such as Midostaurin with the cytokine oncostatin-M holds promise as novel adjunctive therapies for managing this highly aggressive cancer. Notably, oncostatin-M has exhibited the ability to sensitize rat OS cells to apoptosis/necrosis [67]. Recent research indicates that the cytotoxic effects of RG-7388 on SJSA-1 OS cells were counteracted by the GSK-3 inhibitor CHIR-99021 through the reduction of Bak protein levels [68]. These findings align with our previous research, suggesting that Lenalidomide holds sensitivity as a therapeutic agent for OS within the cuproptosis-related lncRNA risk prediction model [18]. Further investigations have revealed the therapeutic efficacy of sunitinib against OS. Utilizing redox-responsive zwitterionic hydrogels for local delivery of sunitinib and ce6 has proven effective in preventing OS recurrence [69]. Moreover, Sunitinib exhibits immunomodulatory effects in tumor-bearing animals by targeting STAT3 and inhibiting PD-L1 expression specifically in OS [70]. Despite these advancements, the association between JNK.Inhibitor. VIII, GDC0941, GW.441756, and OS remains inadequately documented. Nevertheless, findings from this study underscore the sensitivity of these medications for OS, suggesting their potential utility in augmenting the clinical efficacy of OS treatment in future research endeavors.

The present study is subject to certain limitations that warrant acknowledgment. First, the sample size of OS cases incorporated in this investigation is comparatively diminutive when juxtaposed with cohorts examining other neoplastic entities. This discrepancy can be attributed, in part, to the relatively low incidence of OS. It is anticipated that, with the ongoing expansion and refinement of the utilized database, future investigations will benefit from larger and more diverse OS cohorts. Second, elucidating the intricate biological functions of the identified ARGs is imperative for comprehending their capacity to prognosticate and modulate the immune microenvironment in the context of OS. The precise influence of these ARGs on the pathogenesis of OS necessitates further scrutiny through intensified in vivo and in vitro experimentation. Subsequent research endeavors should endeavor to delineate the nuanced roles played by these ARGs in the progressive trajectory of OS disease.

In this investigation, a novel prognostic model for OS has been successfully formulated by incorporating 11 distinct ARGs. The model exhibits robust predictive capabilities, particularly in the context of patient survival and the intricate immune microenvironment. Furthermore, a nomogram model has been developed, characterized by exceptional predictive accuracy in evaluating the prognosis of patients with OS in terms of overall survival. Additionally, the study has identified eight pharmacological agents with promising potential for efficacious intervention in the treatment of OS. These findings make a substantial contribution to the enhancement of clinical outcomes and survival rates among OS patients. The prognostic model established in this investigation carries significant implications for clinical practice, exerting a noteworthy impact on the prognosis of individuals afflicted with OS. Furthermore, it holds considerable promise in refining treatment strategies and elevating the standard of clinical care for OS patients.